---
title: "ARS Pharmaceuticals 1Q 2026: Revenue $22.7M, EPS $(0.61) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286547244.md"
description: "ARS Pharmaceuticals reported Q1 2026 revenue of $22.7M, a 184% increase from $8M in Q1 2025. However, the net loss widened to $60.6M, with diluted EPS at $(0.61). Product revenue rose to $17.5M, and the company is scaling its U.S. launch with 148 sales reps. Over 28,000 prescribers and 120,000 patients are using neffy, with payer coverage near 90%. Operational scale-up is ongoing with regulatory approvals in multiple markets."
datetime: "2026-05-15T10:21:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286547244.md)
  - [en](https://longbridge.com/en/news/286547244.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286547244.md)
---

# ARS Pharmaceuticals 1Q 2026: Revenue $22.7M, EPS $(0.61) — 10-Q Summary

ARS Pharmaceuticals, Inc. reported first-quarter 2026 results with revenue rising sharply year over year while the company widened its net loss and diluted loss per share. Revenue was $22.7M for Q1 2026 versus $8M in Q1 2025, while the company recorded a net loss of $60.6M and diluted EPS of $(0.61).

**Financial Highlights**

-   Revenue: $22.7M for Q1 2026, up from $8.0M in Q1 2025 (184% YoY).
-   Net income: Net loss $60.6M for Q1 2026, vs. net loss $33.9M in Q1 2025 (worsened by $26.7M YoY).
-   Diluted EPS: $(0.61) for Q1 2026, vs. $(0.35) in Q1 2025 (more negative YoY).

**Business Highlights**

-   Product revenue rose to $17.5M in Q1 2026 from $7.8M a year earlier, driving overall revenue growth of 184% YoY.
-   U.S. commercial launch is scaling with a direct sales force of 148 reps, an ALK co-promotion arrangement covering roughly 80 reps, and international launches through partners.
-   Brand adoption momentum: more than 28,000 prescribers and about 120,000 U.S. patients using neffy, with roughly 29.5k patient additions in Q1 2026; payer coverage is near 90% overall.
-   Real-world evidence programs report approximately 90% single-dose effectiveness for neffy; Phase 2b chronic urticaria trial has completed interim enrollment.
-   Operational scale-up underway with commercial manufacturing in place, regulatory approvals in multiple markets (EU, UK, Japan, Australia, China, Canada) and supply agreements supporting global launches.

Original SEC Filing: ARS Pharmaceuticals, Inc. \[ SPRY \] - 10-Q - May. 15, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [SPRY.US](https://longbridge.com/en/quote/SPRY.US.md)

## Related News & Research

- [Key facts: ARS neffy approved US/Canada/EU; rev $22.7M, loss $60.6M](https://longbridge.com/en/news/286637608.md)
- [ARS Pharmaceuticals Q1 revenue beats estimates on neffy sales growth](https://longbridge.com/en/news/286545099.md)
- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)
- [ARS Pharmaceuticals Highlights Strong Neffy Growth and Global Expansion](https://longbridge.com/en/news/286552367.md)
- [OceanPal Inc. Announces 2026 Annual General Meeting of Shareholders to be Held on June 16, 2026 | SVRN Stock News](https://longbridge.com/en/news/286308382.md)